The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...